| Citation: |
XU Hairong, CHEN Jing, NIU Xiaohui. Treatment Choices for Tenosynovial Giant Cell Tumor: Surgery or Observation?[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 1-6. DOI: 10.3971/j.issn.1000-8578.2025.24.0656
|
Tenosynovial giant cell tumor (TGCT) is a rare mesenchymal tumor that clinically presents as nodular-type or diffuse-type (D-TGCT). D-TGCT is more aggressive, has a higher surgical recurrence rate, and can potentially lead to severe joint destruction. The traditional treatment is primarily through surgical intervention. Recent advancements in understanding the molecular mechanisms of the disease and the development of new drugs have significantly changed TGCT treatment strategies. Drug therapy and active surveillance have become important treatment options for unresectable or high-recurrence-risk TGCT. Imaging examinations and patient-reported outcome tools play a crucial role in evaluating efficacy and guiding treatment decisions. Comprehensive management by a multidisciplinary team and utilizing individualized treatment plans can significantly improve the quality of life and treatment outcomes of patients. Future research should explore the molecular mechanisms of TGCT, enhance multidisciplinary collaboration, and emphasize long-term management to improve treatment efficacy and patient prognosis.
Competing interests: The authors declare that they have no competing interests.
| [1] |
Sbaraglia M, Bellan E, Tos APD. The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives[J]. Pathologica, 2021, 113(2): 70-84.
|
| [2] |
Stacchiotti S, Dürr HR, Schaefer IM, et al. Best clinical management of tenosynovial giant cell tumour (TGCT): A consensus paper from the community of experts[J]. Cancer Treat Rev, 2023, 112: 102491. doi: 10.1016/j.ctrv.2022.102491
|
| [3] |
Baldi GG, Gronchi A, Stacchiotti S. Pexidartinib for the treatment of adult symptomatic patients with tenosynovial giant cell tumors[J]. Expert Rev Clin Pharmacol, 2020, 13(6): 571-576. doi: 10.1080/17512433.2020.1771179
|
| [4] |
Spierenburg G, Staals EL, Palmerini E, et al. Active surveillance of diffuse-type tenosynovial giant cell tumors: A retrospective, multicenter cohort study[J]. Eur J Surg Oncol, 2024, 50(2): 107953. doi: 10.1016/j.ejso.2024.107953
|
| [5] |
Spierenburg G, van der Heijden L, van Langevelde K, et al. Tenosynovial giant cell tumors (TGCT): molecular biology, drug targets and non-surgical pharmacological approaches[J]. Expert Opin Ther Targets, 2022, 26(4): 333-345. doi: 10.1080/14728222.2022.2067040
|
| [6] |
Gouin F, Noailles T. Localized and diffuse forms of tenosynovial giant cell tumor (formerly giant cell tumor of the tendon sheath and pigmented villonodular synovitis)[J]. Orthop Traumatol Surg Res, 2017, 103(1): S91-S97. doi: 10.1016/j.otsr.2016.11.002
|
| [7] |
Schenk P, Schöni M, Urbanschitz L, et al. Tenosynovial Giant Cell Tumor (TSGCT) of the hip: MRI accuracy and results of surgical treatment[J]. Acta Orthop Belg, 2023, 89(1): 65-69. doi: 10.52628/89.1.10424
|
| [8] |
Boland JM, Folpe AL, Hornick JL, et al. Clusterin is Expressed in Normal Synoviocytes and in Tenosynovial Giant Cell Tumors of Localized and Diffuse Types[J]. Am J Surg Pathol, 2009, 33(8): 1225-1229. doi: 10.1097/PAS.0b013e3181a6d86f
|
| [9] |
van IJzendoorn DGP, Matusiak M, Charville GW, et al. Interactions in CSF1-driven Tenosynovial Giant Cell Tumors[J]. Clin Cancer Res, 2022, 28(22): 4934-4946. doi: 10.1158/1078-0432.CCR-22-1898
|
| [10] |
Mastboom MJL, Palmerini E, Verspoor FGM, et al. Surgical outcomes of patients with diffuse-type tenosynovial giant-cell tumours: an international, retrospective, cohort study[J]. Lancet Oncol, 2019, 20(6): 877-886. doi: 10.1016/S1470-2045(19)30100-7
|
| [11] |
Ozben H, Coskun T. Giant cell tumor of tendon sheath in the hand: analysis of risk factors for recurrence in 50 cases[J]. BMC Musculoskelet Disord, 2019, 20(1): 457. doi: 10.1186/s12891-019-2866-8
|
| [12] |
Patel KH, Gikas PD, Pollock RC, et al. Pigmented villonodular synovitis of the knee: A retrospective analysis of 214 cases at a UK tertiary referral centre[J]. Knee, 2017, 24(4): 808-815. doi: 10.1016/j.knee.2017.03.011
|
| [13] |
Houdek MT, Scorianz M, Wyles CC, et al. Long-term outcome of knee arthroplasty in the setting of pigmented villonodular synovitis[J]. Knee, 2017, 24(4): 851-855. doi: 10.1016/j.knee.2017.04.019
|
| [14] |
Ono Y, Miyakoshi N, Tsuchie H, et al. Pigmented Villonodular Synovitis Around the Elbow Joint That Required Upper Arm Amputation[J]. J Med Cases, 2020, 11(7): 201-203. doi: 10.14740/jmc3503
|
| [15] |
Chien JC, Wei YP, Chen CY, et al. Long-term functional outcomes of diffuse pigmented villonodular synovitis of knee[J]. Medicine(Baltimore), 2021, 100(12): e23794.
|
| [16] |
Park G, Kim YS, Kim JH, et al. Low-dose external beam radiotherapy as a postoperative treatment for patients with diffuse pigmented villonodular synovitis of the knee[J]. Acta Orthop, 2012, 83(3): 256-260. doi: 10.3109/17453674.2012.678803
|
| [17] |
Tie K, Wang H, Chen B, et al. Midterm outcomes of 18 patients with primary intra-articular diffuse tenosynovial giant cell tumor (TGCT) of the knee treated with complete arthroscopic synovectomy and postoperative low-dose radiotherapy at a mean follow-up of 68 months[J]. Arch Orthop Trauma Surg, 2023, 143(4): 2121-2127.
|
| [18] |
Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee[J]. Arthroscopy, 2001, 17(5): 527-531. doi: 10.1053/jars.2001.24068
|
| [19] |
Horoschak M, Tran PT, Bachireddy P, et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis[J]. IntJ Radiat Oncol Biol Phys, 2009, 75(1): 183-187. doi: 10.1016/j.ijrobp.2008.10.058
|
| [20] |
De Carvalho Jr LH, Soares LF, Gonçalves MB, et al. Long-term success in the treatment of diffuse pigmented villonodular synovitis of the knee with subtotal synovectomy and radiotherapy[J]. Arthroscopy, 2012, 28(9): 1271-1274. doi: 10.1016/j.arthro.2012.02.007
|
| [21] |
Griffin AM, Ferguson PC, Catton CN, et al. Long-term outcome of the treatment of high-risk tenosynovial giant cell tumor/pigmented villonodular synovitis with radiotherapy and surgery[J]. Cancer, 2012, 118(19): 4901-4909. doi: 10.1002/cncr.26529
|
| [22] |
Baniel C, Yoo CH, Jiang A, et al. Long-term Outcomes of Diffuse or Recurrent Tenosynovial Giant Cell Tumor Treated with Postoperative External Beam Radiation Therapy[J]. Pract Radiat Oncol, 2023, 13(3): e301-e307. doi: 10.1016/j.prro.2022.11.004
|
| [23] |
Mollon B, Lee A, Busse JW, et al. The effect of surgical synovectomy and radiotherapy on the rate of recurrence of pigmented villonodular synovitis of the knee: an individual patient meta-analysis[J]. Bone Joint J, 2015, 97-B(4): 550-557. doi: 10.1302/0301-620X.97B4.34907
|
| [24] |
Tap WD, Wainberg ZA, Anthony SP, et al. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor[J]. N Engl J Med, 2015, 373(5): 428-437. doi: 10.1056/NEJMoa1411366
|
| [25] |
Tap WD, Gelderblom H, Palmerini E, et al. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial[J]. Lancet, 2019, 394(10197): 478-487. doi: 10.1016/S0140-6736(19)30764-0
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: